In a pivotal development, federal researchers have proposed the reclassification of marijuana, recognizing its medical potential and lower risk profile compared to drugs like heroin. This recommendation, detailed in a 250-page scientific review, marks a significant shift in the federal stance on cannabis.

Published on January 12, 2024, the New York Times article reveals that the Food and Drug Administration and the National Institute on Drug Abuse suggest reclassifying marijuana as a Schedule III drug. This category includes substances like ketamine and testosterone, available by prescription.

The review highlights marijuana’s lower likelihood of causing serious outcomes compared to Schedule I or II drugs and acknowledges its therapeutic applications in treating anorexia, pain, and chemotherapy-induced nausea and vomiting. While not an outright endorsement for FDA approval, this reassessment by federal scientists could significantly impact the legal and medical landscape of marijuana use in the United States.